Cases

LifeTec Group is involved in the treatment of cardiac arrythmia by ablation which involves creating tiny scars to block abnormal electrical signals, and in the development of MR guided Electrophysiology ablation to distinguish between scarred and swollen tissue during the procedure.

LifeTec Group, through its multidisciplinary collaboration with SINERGIA consortium, is focusing on the research of an ex vivo perfused liver platform, called BioLiver, to reduce and refine animal testing, provide more insights compared to conventional in vitro models, and to offer new services for studies of liver interventions and tissue response to drug treatment.

LifeTec Group has joined the SAFE-CAB project, aimed at developing a new, minimally invasive coronary artery bypass procedure, and they will co-develop a training procedure and a realistic training environment to prepare surgeons and cardiologists to use the new technology.

The PLS project aims to develop a liquid-based incubator for prematurely born babies.

Carmat is the designer and developer of the world’s most advanced total artificial heart. With this product, they aim to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure.

AngioSupport is a clinical decision tool to support the cardiac team with treatment planning for patients with coronary artery disease (CAD).

The iMIT project aims to develop a new generation of devices that combine diagnosis and therapy in one procedure to improve diagnosis and treatment in minimally invasive procedures, and within LASER, the focus is on developing new instruments for fetoscopic laser coagulation to improve the outcome of the procedure.

The VPH-CaSE project, in which LifeTec Group is involved, focuses on personalized cardiovascular support and improvements to the PhysioHeart™ ex vivo beating heart model are being made to enhance its usability and lifespan, in order to evaluate cardiological and cardiac surgical treatments more reliably.

The CarBon project aims at developing new treatment options for large bone defects and osteoarthritis. Within the project LifeTec Group is aiming at developing disease models in order to assess new treatment options.

The Philips Research team developed an innovative ultrasound imaging solution, and established a passive-heart setup at their facilities with the help of LifeTec Group to get controllable, in-vivo like data in a controlled and safe environment, without ethical concerns, and for a lower budget.

LifeTec Group performed a thorough validation and verification study on Oxiplenish's donor organ transport system (Airdrive), covering all necessary parameters and including consultation with regulatory advisory and notified bodies, resulting in optimized performance and continued cooperation with Oxiplenish on the road to CE marking.

LifeTec Group helped Eucardia quickly and affordably assess and improve their Heart Damper device using the Cardiac BioSimulator and PhysioHeart platforms.

The MUSICARE program developed an innovative catheter-based therapy for cardiovascular pathologies, and LifeTec Group is conducting research on the use of light and materials to improve its effectiveness.

BIOGEL is a European research program developing hydrogels for medical applications, with LifeTec Group creating physiologically relevant 3D in vitro and ex vivo platforms to study biomaterial behavior and tissue interaction, improving biomaterial test methods for a more predictable translation to pre-clinical practice.

The BIP-UPy project has developed bioactive implants for intracranial aneurysms and pelvic organ prolapse/stress urinary incontinence, and LifeTec Group has developed in vitro/ex vivo model systems to assess their mechanical loading conditions and performance under long-term ex vivo culture.

The efficacy of the Intra-Aortic Balloon Pump (IABP) therapy was systematically assessed in different simulated conditions using the PhysioHeart platform, with the results indicating that IABP support is mostly effective in case of ischemia, leading to a new randomized clinical study at the Catharina Hospital.

HydroZONES aims to regenerate articular cartilage using bio-functional hydrogel-based implants and LifeTec Group developed a 3D ex vivo long-term culture and test system for cartilage implants, allowing for better interpretation of outcomes and predictable translation into pre-clinical practice, thus saving time, risks, costs and animal lives.

Meliora Medical aimed at bringing to the clinic an innovative surgical motion-preserving solution for neck and back pain, based on a biomimetic design with a shock-absorbing core, which was developed by TU/e researchers.

Development of an innovative sterile bioreactor for heart valve culturing (Tissue Engineering).